Heron Therapeutics (HRTX) Receivables - Net (2010 - 2026)

Heron Therapeutics has reported Receivables - Net for 12 years, with the latest figure at $83.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 6.3% year-over-year to $83.7 million; the trailing twelve-month figure through Mar 2026 stood at $83.7 million (up 6.3% YoY), and the FY2025 full-year result was $89.6 million, up 13.57% from the prior year.
• Receivables - Net for Q1 2026 stood at $83.7 million, down from $89.6 million in the prior quarter.
• The five-year high for Receivables - Net was $89.6 million in Q4 2025, with the low at $40.3 million in Q2 2022.
• Historically, Receivables - Net has averaged $66.2 million across 5 years, with a median of $67.0 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net decreased 5.43% — and 2023, when it jumped 90.29%.
• Heron Therapeutics' Receivables - Net stood at $52.0 million in 2022, then rose by 15.54% to $60.1 million in 2023, then soared by 31.17% to $78.9 million in 2024, then grew by 13.57% to $89.6 million in 2025, then declined by 6.58% to $83.7 million in 2026.
• The last three Receivables - Net figures came in at $83.7 million (Q1 2026), $89.6 million (Q4 2025), and $81.0 million (Q3 2025), per Business Quant data.